Business Insider

Promius Pharma Announces ZEMBRACE® SymTouch® (Sumatriptan Injection) 3 mg Achieves Primary Endpoint in Post-Approval Clinical Trial

PRINCETON, N.J., Nov. 15, 2017 /PRNewswire/ -- Promius Pharma LLC announced today that ZEMBRACE ® SymTouch ® (sumatriptan injection) 3 mg, an acute migraine headache treatment on the market since ...
Seeking Alpha

Tonix Pharmaceuticals Announces Commitment to Supply Tosymra® (sumatriptan Nasal Spray) 10 mg for Treatment of Acute Migraine to Meet Potential Increased Demand Following GSK ...

Tosymra Nasal Spray 10 mg is a Proprietary Acute Migraine Treatment Approved Under the 505(b)2 Pathway Based on Bioequivalence to Imitrex (sumatriptan) Injection 4 mg GlaxoSmithKline Recently Notified ...
Seeking Alpha

Tonix Pharmaceuticals Completes Acquisition of Two FDA-Approved, Marketed Migraine Products

Strategic Acquisition Helps Build Tonix’s Commercial Capabilities and Infrastructure Ahead of Potential Launch of TNX-102 SL for the Management of Fibromyalgia Acquisition of Zembrace® SymTouch® ...
News Medical

FDA approves ZEMBRACESymTouch (sumatriptan succinate) injection for treatment of acute migraines

Dr. Reddy's Laboratories (NYSE: RDY), announced today that the U.S. Food and Drug Administration (FDA) has approved ZEMBRACE™SymTouch™ (sumatriptan succinate) injection, a drug-device combination ...
NBC News

Zogenix to Present Additional SUMAVEL(R) DosePro(R) Phase 4 Results at Headache Meetings in June

SAN DIEGO, May 27, 2011 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX) today announced that additional data from the Company's Phase 4 clinical study of SUMAVEL ® DosePro® (sumatriptan injection) ...
NBC News

Zogenix Receives 2010 Most Innovative Product Award for SUMAVEL(R) DosePro(TM)

SAN DIEGO, Dec. 13, 2010 (GLOBE NEWSWIRE) -- Zogenix, Inc. ("Zogenix") (Nasdaq:ZGNX) today announced that CONNECT, a regional San Diego nonprofit organization, selected SUMAVEL ® DosePro™ (sumatriptan ...
Reuters

Spectrum says court dismisses Glaxo patent suit

Dec 21 (Reuters) - Spectrum Pharmaceuticals Inc. said the U.S. District Court at its request has dismissed the patent litigation with GlaxoSmithKline , allowing it to move forward under the settlement ...